IMMUNOASSAY

FIELD OF THE INVENTION

5   The present invention relates to a method for determination of haptens using a rapid
flow-through immunoassay format.

BACKGROUND

10   In sandwich or "catching antibody—antigen—labelled antibody" assays, two
independent epitopes bound by different antibodies provide the advantages in terms of
speed, sensitivity, and specificity. However, sandwich assay formats have not been
directly applicable to small molecular weight haptens. Haptens are not large enough
to bind simultaneously to two antibodies independently. For these reasons,
15   competitive assays are the most widely used format for measurement of haptens.

To enhance assay sensitivities and specificities for haptens, non-competitive methods
have been used. For example, *anti*-immune complex assays (*Proc. Natl. Acad. Sci.
USA*, 90, 1993, 1184-1189 and *Clin. Chem.* 40(11), 1994, 2035-2041) were
20   successfully used for determinations of tetrahydrocannabinol (THC) and digoxin.
Selective antibody or 'idiometric' methodology (*J Immunol Methods* 181, 1995, 83-
90 and *Steroids* 60, 1995, 824-829) is another non-competitive approach, which
provided more sensitive assays for estradiol and progesterone than conventional
competitive enzyme assays. However, these non-competitive formats require unique
25   antibodies and antiidiotypes that are potentially difficult to obtain. Another non-
competitive two-site enzyme immunoassay format (hetero-two-site or immune
complex transfer) (*Biotechnology Annual Review* 1,1995, 403-451) has been also
applied for small peptides or haptens with good detection levels. Unfortunately the
immunoassay requires multiple steps. Multiple steps mean the assay is generally more
30   expensive and time consuming than is desirable. The immunoassay also involves the
use of harsh chemicals which potentially damage sensitive biomolecules and also
involve the use of strongly acidic, basic or organic solvents that complicate providing
assays in non-laboratory settings.

Another non-competitive assay for small molecules has been employed for measurement of cortisol and estradiol as described in US 6,037,185. This assay permits the direct measurement of hapten bound sites or initial amount of hapten in the sample. Unfortunately, the assay still requires multiple steps to perform, which is

5   potentially costly and time consuming.

Optical immunosensors are popular for bio-analysis. The non-destructive nature of the technology permits multiple reuses of samples for other readings. Rapid signal generation and thus rapid result generation are also advantages of the system.

10 Unfortunately, label-free optical immunosensors have relatively poor analytical sensitivities to haptens with low molecular weight compared to traditional immunoassays such as ELISA. Despite significant developments in this field, optical immunosensors tend to be one magnitude less sensitive than commercial immunoassays for determining haptens.

15

It is an object of the present invention to provide an immunoassay that overcomes at least some of the above-mentioned disadvantages of existing assays; and/or that provides similar or better sensitivities to those of existing non-competitive formats; and/or that is rapid; and/or that has fewer steps than assays in the art, or that at least

20 provides the public with a useful choice.

DISCLOSURE OF THE INVENTION

In a first aspect, the present invention provides a method for detecting a hapten in a

25 sample comprising the steps of:

a) providing a sample potentially containing a hapten of interest;

b) providing a pre-determined amount of a first moiety, said first moiety being bound to a signaller and separated therefrom by a first linker, which first moiety is either:

30   i.   a binding partner that specifically binds to the hapten of interest, or

ii. the hapten of interest or an analogue thereof;

wherein said signaller is a macromolecule or a nanoparticle providing high mass signal.

2

     c) providing a flow of a) and b) separately or together to an immobilised second moiety, said second moiety being bound to the surface of a sensor and separated therefrom by a second linker, which second moiety is either:

       i. a binding partner that specifically binds to the hapten of interest, or

5   ii. is the hapten of interest or an analogue thereof,

       providing that when the first moiety is a binding partner, the second moiety is a hapten or hapten analogue and when the first moiety is a hapten or hapten analogue, the second moiety is a binding partner; and

     d) detecting the amount of first moiety bound to second moiety.

10

In a further aspect, the present invention provides a method for detecting a hapten in a sample comprising the steps of:

     a) providing a sample potentially containing a hapten of interest;

     b) providing a pre-determined amount of a binding partner that specifically binds

15   to the hapten of interest, said binding partner being bound to a signaller and separated therefrom by a first linker wherein said signaller is a macromolecule or a nanoparticle providing a high mass signal;

     c) providing a flow of a) and b) separately or together to an immobilised hapten of interest or an analogue thereof, said hapten or analogue thereof being bound

20   to the surface of a sensor and separated therefrom by a second linker; and

     d) detecting the amount of binding partner bound to said immobilised hapten or an analogue thereof.

In a still further aspect, the present invention provides a method for detecting a hapten

25 in a sample comprising the steps of:

     a) providing a sample potentially containing a hapten of interest;

     b) providing a pre-determined amount of the hapten of interest or an analogue thereof, said hapten or analogue thereof being bound to a signaller and separated therefrom by a first linker wherein said signaller is a macromolecule

30   or a nanoparticle providing a high mass signal;

     c) providing a flow of a) and b) separately or together to an immobilised binding partner that specifically binds to the hapten of interest, said binding partner being bound to the surface of a sensor and separated therefrom by a second linker; and

3

d) detecting the amount of hapten or analogue thereof bound to said immobilised binding partner.

In a yet further aspect, the present invention provides a method for detecting a hapten
5   in a sample comprising the steps of:

a) providing a sample potentially containing a hapten of interest;

b) providing a pre-determined amount of a first moiety, said first moiety being bound to a signaller, which first moiety is either:

    i.   a binding partner that specifically binds to the hapten of interest, or

10   ii. the hapten of interest or an analogue thereof;

wherein said signaller is a macromolecule or a nanoparticle providing a high mass signal;

c) providing a flow of a) and b) separately or together to an immobilised second moiety, said second moiety being bound to sensor surface, which second
15   moiety is either:

    i.   a binding partner that specifically binds to the hapten of interest, or

    ii. is the hapten of interest or an analogue thereof,

    providing that when the first moiety is a binding partner, the second moiety is a hapten or hapten analogue and when the first moiety is a
20   hapten or hapten analogue, the second moiety is a binding partner; and

d) detecting the amount of first moiety bound to second moiety,

characterised in that said first moiety is bound to and separated from said signaller by a first linker and said second moiety is bound to and separated from said immobilisation substrate by a second linker.

25

In another aspect, the present invention provides a kit for determining the presence of a hapten of interest in a sample, which kit at least includes:

a) a first moiety being bound to a macromolecule or a nanoparticle and separated therefrom by a first linker, which first moiety is either:

30   i.   a binding partner that specifically binds to the hapten of interest, or

    ii. the hapten of interest or an analogue thereof; and

b) a sensor with an immobilised second moiety, said second moiety being bound to the sensor and separated therefrom by a second linker, which second moiety is either:

i.   a binding partner that specifically binds to the hapten of interest, or

ii.   is the hapten of interest or an analogue thereof,

providing that when the first moiety is a binding partner, the second moiety is a hapten or hapten analogue and when the first moiety is a hapten or hapten

5   analogue, the second moiety is a binding partner.

In another aspect, the present invention provides a kit for determining the presence of a hapten of interest in a sample, which kit at least includes:

a)   a first moiety being bound to a signaller, which first moiety is either:

10   i.   a binding partner that specifically binds to the hapten of interest, or

ii.   the hapten of interest or an analogue thereof;

wherein the signaller is a macromolecule or a nanoparticle; and

b)   a sensor with an immobilised second moiety, said second moiety being bound to the sensor, which second moiety is either:

15   i.   a binding partner that specifically binds to the hapten of interest, or

ii.   is the hapten of interest or an analogue thereof,

providing that when the first moiety is a binding partner, the second moiety is a hapten or hapten analogue and when the first moiety is a hapten or hapten analogue, the second moiety is a binding partner,

20   characterised in that said first moiety is bound to and separated from said signaller by a first linker and said second moiety is bound to and separated from said immobilisation substrate by a second linker.

In preferred embodiments of the above aspects of the invention the sample a) and the

25   predetermined amount of the second moiety b) are mixed and in step c) the mixture is caused to flow to the immobilised second moiety.

In one embodiment, the present invention provides a method for detecting a hapten in a sample using a rapid flow-through inhibition assay format comprising the steps of:

30   a)   Providing a functionalised hapten derivative with a linking group (first linker) between the hapten molecule and its functional group;

b)   Providing an immobilised hapten derivative on the surface of an optical biosensor chip wherein the hapten derivative is linked to the surface through a linking group (first linker) between the hapten molecule and the surface;

c) Mixing high molecular weight detecting molecules, for example antibodies, with sample analytes to form immuno-complexes, and then providing flow-through of the mixing solution containing excess free antibodies to bind to the sensor surface;

5   d) Further binding enhancement performed by flowing-through onto the sensor surface with a solution containing a conjugate employing a linker (second linker), a moiety to specifically recognise a detecting molecule such as an antibody is linked at one end of the conjugate, and the other end of the conjugate is attached to a protein or/and a *nano*-particle for high mass signal enhancement;

10

In another embodiment, the present invention provides a rapid flow-through competition immunoassay method for detecting a hapten in a sample comprising the steps of:

a) Providing immobilised detecting molecules for example antibodies on the
15   biosensor surface with a linker (first linker) between a biomaterial as an attachment intermediate and the detecting molecule;

b) Mixing sample analytes with a hapten conjugate, in which a protein or/and a nano-particle is linked to the hapten molecule with a linker (second linker) and having a *nano*-distance (nm) between the protein/*nano*-particle and the hapten
20   molecule to reduce steric hindrance;

c) Flowing through the mixture of hapten conjugate and sample analyte solution onto the sensor surface for binding competition to limited detecting molecules such as antibodies on the surface of the sensor;

25 .   In preferred embodiments, rapid on-line regeneration is used to completely remove hapten conjugates to allow multiple measurements. This may be carried out byinjection of regeneration solutions that may include sodium hydroxide and acetonitrile.

A standard curve may be prepared from solutions with a series of known analyte
30   concentrations, and the concentrations of analyte in unknown samples may then derived from the standard curve.

The present invention includes a new design based on a novel concept of *Dual-Linker Technology with High Mass Labelling* (Figure 1) for flow-through optical biosensors

such as Surface Plasmon Resonance (SPR) based immunoassays to achieve high binding signal and assay sensitivity enhancement particularly for small molecular weight analytes, such as therapeutic and abused drugs, steroids, thyroid hormones, metabolites and pollutants etc.

5

As stated above, the present invention provides, in a first aspect, a method for detecting a hapten in a sample. The method comprises several essential steps.

The first step is providing a sample potentially containing a hapten of interest. A pre-
10   determined amount of a first moiety is provided. The first moiety is provided bound to the signaller and separated therefrom by a first linker. The first moiety is either a binding partner that specifically binds to the hapten of interest or the hapten of interest or an analogue thereof.

15   The two components or a mixture thereof is now contacted with an immobilised second moiety. The second moiety is provided bound to the detection surface of a sensor and separated therefrom by a second linker. The second moiety is either a binding partner that specifically binds to the hapten of interest, or is the hapten of interest or an analogue thereof. However, when the first moiety is a binding partner,
20   the second moiety must be a hapten or hapten analogue. Alternatively, when the first moiety is a hapten or hapten analogue, the second moiety must be a binding partner. The amount of first moiety bound to second moiety is then detected.

The linker can be bound directly to the detection surface of a sensor, for example by a
25   covalent bond formed from an amine group at the end of the linker and a carboxyl group on the surface. Alternatively the linker may be bound to another molecule for example a protein (for example ovalbumin) which may bind to the surface. Thus the linker may connect directly with the surface or other components may be inserted between the first moiety and the surface.

30

In the context of this invention, the term "hapten" means any small molecular hapten which has a molecular weight less than 5000 Daltons. Most usually, the hapten is an organic compound of low molecular weight (less than 2000 Daltons) that reacts specifically with an antibody and which is incapable of eliciting an immune response

by itself but is immunogenic when complexed with an antigenic carrier. Haptens of interest here are selected from the group comprising carbohydrates, polynucleotides, steroids, steroid analogues, polypeptides (such as peptide hormones), drugs and toxins, but are not limited thereto. Haptens of particular interest in the present

5   invention include therapeutic drugs, narcotics, steroids, thyroid hormones, metabolites and pollutants. The invention has particular application with smaller haptens as steric hindrance caused by attachment is more of a problem with smaller haptens.

Herein, "binding partner" refers to macromolecules capable of specifically binding to

10 a target hapten of interest. Examples of suitable macromolecules include antibodies and fragments thereof as well as nucleic acids, such as an RNA aptamer described in *Biochemical and Biophysical Research Communications* 281, 237-243 (2001) and incorporated herein by reference.

15 Antibodies are well known to those of ordinary skill in the science of immunology. As stated above, included within the ambit of "binding partner" are not only intact antibody molecules but also fragments of antibody molecules retaining hapten-binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*.

20

Therefore, "binding partner" also includes not only intact immunoglobulin molecules but also the well-known active fragments F(ab')₂, and Fab. F(ab')₂, Fab fragments which lack the Fc fragment of intact antibody, Fv, single chain (ScFv), mutants thereof, fusion proteins comprising an antibody portion, and any other modified

25 configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity. In an alternative embodiment, the binding partner may be a T-cell receptor. Other types of binding protein may be used where these can be identified, and have sufficient specificity for the hapten of interest.

30 "specifically binds" or "specifically binding" in the present invention means that the binding partner binds to the hapten of interest without substantial cross reactivity to other species in the sample to enable a meaningful detection result to be obtained.

"analogue" of a hapten herein refers to a group that competes with the hapten for binding to a binding partner. In the case of antibodies, the analogue should bind to the same site on the antibody as the hapten.

5   "sample" is typically a liquid sample from a biological source, but is not limited thereto.

"surface of a sensor" is the surface of any bulky suitable substantially insoluble support forming part of a sensor that permits attachment of a linker. The surface may
10 include but is not limited to a chip surface, gels (e.g. cross-linked chromatography gels) and a solid support as well as any other support well known in the art. Non-limiting examples of suitable immobilisation substrates suitable for the practice of the present invention include:

(a) insoluble polymeric materials such as polystyrene, polypropylene, polyester,
15 polyacrylonitrile, polyvinyl chloride, polyvinylidene, polysulfone, polyacrylamide, cellulose, cellulose nitrate, cross-linked dextrans, fluorinated resins, agarose, crosslinked agarose, and polysaccharides etc;

(b) glass, glass fibres, and glass beads;

(c) metal (gold, silver or platinum), metal strips and metal beads;
20 (d) nylon mesh material and nylon membranes; and

(e) test tubes, microtiter plates, dipsticks, lateral flow devices, resins, PVC, latex beads and nitrocellulose.

Preferably the sensor is based around a surface of an optical biosensor chip.
25 Preferably the chip is adapted for use in an optical system in which high mass groups can be detected on a surface. Most preferably the chip is adapted for use in a surface plasmon resonance detection system.

A preferred sensor chip is a BIAcore CM5 chip.
30

The invention is directed to "rapid" assays, characterised in that they are flow-through or flow-over assay formats, giving rapid signal generation and a reading typically in less than 1 0 minutes. The invention is particularly suited to a rapid flow-through assay using a commercial BIAcore instrument.

In one embodiment of the present invention, hapten molecules are chemically immobilised onto a sensor surface with a linker interposed between the hapten and the surface. In an alternative embodiment, the hapten is attached to an attachment

5   intermediate material with a linker interposed between the hapten and the attachment intermediate material. The attachment intermediate is, in turn, attached to a sensor surface. Preferred attachment intermediates are selected from the group comprising proteins (*Steroids,* 67, 2002, 565-572), nucleic acid fragments (US Patent: 5,849,480) and *N*-vinylpyrrolidone copolymer (US Patent: 5,723,334). Examples of suitable

10 proteins as attachment intermediate materials include bovine serum albumin (BSA), ovalbumin (OVA) or keyhole limpet hemocyanin (KLH). Proteins may also include enzymes, secretory proteins, globular proteins. A preferred protein for use herein is ovalbumin (OVA).

15 Where the hapten is a steroid, it is preferred that binding of the hapten to the linker occurs at the 4-position of the structure. The binding at the 4-position of the A ring is particularly preferred when binding estrogens, progesterone and steroids having an A-ring structure similar to progesterone. Moieties of formulae **14-17, 20-23 and 29-32** are currently preferred steroids for binding at the 4-position on the A ring (see

20 Examples).

When the hapten is an aromatic neurotransmitter molecule such as dopamine or serotonin, it is preferred that binding of the hapten occurs at the aromatic ring.

25 In the currently most preferred embodiment, the hapten is progesterone.

The "first linker" and "second linker" are typically each independently 4 to 50 atoms in length, preferably 10 to 50, more preferably 10 to 30 atoms in length excluding any bridging groups. Linkers suitable for the practice of the present invention are

30 preferably (a) a carbon-based chain; (b) carbon-chain containing one or more heteroatoms such as N, S, O; (c) carbon-chain with substituted groups; (d) an amino acid chain, amino acid fragments incorporated into the chain, or multiple amino-acid fragments chain by for example homologation; (e) a polyethylene glycol chain; (f) a chain have one or more sites of unsaturation such as alkenyl; (g) a nucleic acid chain;

10

or (h) a polysaccharide chain etc. Obviously, depending on the nature and physical size of the moiety attached to the chain, the chain can be made hydrophobic or hydrophilic by including fewer or more groups respectively that are more polar or ionic in the chain.

5

The second linker can be selected from different molecular types and lengths. It has been found that the best performance is obtained when the second linker is selected to ensure that non-bulky groups are proximal the hapten. It is preferred that the chain be carbon-based. The carbon-based chain may comprise one or more heteroatoms

10   selected from N, S, and O. Side chain substituent groups may also be provided. Other preferred chains are selected from the group comprising amino acids, a polyethylene glycol, alkyl, alkenyl, nucleic acid, and polysaccharide. The chain can have one or more sites of unsaturation. Multiple amino-acid fragments may be provided by homologation. The use of hybrid peptide-nucleic acid fragments as linkers is also

15   contemplated.

The use of nano-sized "dual linker" or a first linker - between the chip surface and the centre of the immuno-complex, and a second linker – between the centre of immuno-complex and a large protein or/and a nano-particle will greatly reduce the steric

20   hindrance to enhance antibody binding, and hence increases the assay sensitivities, assay speed and easy regeneration for multiple measurements. Typically each linker provides a chain of length 0.5-100nm, preferably most preferably 1-5 nm.

One preferred synthesis of the first and second linkers for use in the present invention

25   in different length is controlled and performed by successive aminocaproic acid homologation of hapten acid derivatives as illustrated in Reaction Scheme 1 before conjugation to proteins or immobilised onto the sensor surface directly.

30

Reaction Scheme 1

(1)

1). H₂N(CH₂)₅CO₂H
2). DCC/NHS

(2)

Ovalbumin (OVA)

(3)

5   The structure of progesterone-ovalbumin conjugate with a 25-atoms linker (3),
and its synthesis from the conjugate (4) (*Steroids*, 67, 2002, 565-572). The
conjugate (3) was immobilised onto the SPR biosensor surface.

A more preferred synthesis of a hapten derivative to use in the present invention is
10   controlled and performed by inserting a polyethylene glycol (PEG) chain in different
length as a linker and immobilised the hapten derivative onto the sensor surface
directly (Reaction Scheme 2). Such hapten derivative having a PEG unit as a linker
has some distinctive advantages such as 1) PEG chain as a linker can make hapten
derivative more water-soluble, and therefore the hapten derivative can be easily *in-*

situ or on-line immobilized onto the sensor surface, which is convenient in real time for process monitoring and quality control in terms of reproducibility performance of immobilization. Use of a PEG chain as a linker can also provide hydrophilic molecular layers to reduce non-specific binding and create more space and a favourable binding medium between the chip surface and the immuno-complex for better antibody binding.

Reaction Scheme 2

1). DCC/NHS

2). H_2N —O—O—O—$\overset{H}{N}$OC(CH$_3$)$_3$

Formic acid

In-situ immobilization

Sensor surface

Linker-1

**Synthesis of a progesterone-PEG (linker-1) derivative and its
In-situ immobilization onto a sensor surface**

The progesterone-PEG (linker-1) derivative of Reaction Scheme 2 may be synthesised from progesterone-4-thiopropanoic acid (1) (*Steroids*, 67, 2002, 565-572) and *in-situ* immobilized onto a sensor surface.

5   There are many well-known immobilisation techniques in the art. Preferred immobilisation techniques for immobilising the first moiety, hapten to be immobilised or binding partner to be immobilised onto a sensor surface is by a covalent coupling reaction (e.g. to an amine, a carboxyl or sulfhydryl group on the protein), nucleic acid hybridisation, or ligand interaction. Immobilisation on the sensor surface may be also

10   by passive adsorption, or via a ligand interaction, such as an avidin/biotin complex (US Patent: 4,467,031).

Any suitable linker known in the art may be employed. Other examples of hapten-linker molecules useful in the practice of the present invention having different end-

15   functional groups are shown Formulae 14-17, 20-23, 29-32, 34, 35, 37 and 38 (see Examples).

In order to covalently bind hapten to first and second linking groups in the practice of the present invention, it is often necessary to include a thioether or ether bridging

20   group, preferably a thioether group, generally through their mono-bromide intermediate compounds.

"signaller" herein means a group capable of providing high mass labels for signal enhancement. Preferred embodiments include large proteins of molecular weight at

25   least 20kD, preferably at least 50kD, more preferably at least 100kD and nanoparticles (metal or non-metal; colour or non-colour) such as immunogold and coloured latex beads. Preferably the nanoparticles have a diameter/long axis of 1nm-1000nm, preferably 10-500nm most preferably 10-20nm.

30   The term "nanoparticles" refers to the particles used to provide sensitivity through mass labels and are solid particles ranging widely in the size of nanoscale, which includes metal particles (colloidal gold), non-metal particles (latex beads), or any other suitable nanoparticles used as mass labels for signal enhancement.

The term "macromolecule" refers to a molecule with a molecular weight of at least 20kD. Macromolecules for use as signallers in this invention are preferably of molecular weight 50kD, more preferably at least 100 kD.

5   Detecting the amount of bound double linker moieties of the present invention may be undertaken utilising a number of different techniques available in the art.

In one embodiment, immunogold particles are used because they are inexpensive and relatively stable.

10

The inventors have discovered that provision of a double linker molecule of the present invention increases binding partner binding performance in short-duration assays, such as flow-through assays leading to better assay sensitivities than with single linker or no linker systems. It has also been discovered that a most preferred

15   detection system, surface plasmon resonance (SPR) utilising nano-particles gives unexpectedly good sensitivities when used in conjunction with double linker technologies.

It has also been found by the inventors that the use of double linkers in the methods of

20   the present invention permits easier regeneration of a detection system for multiple readings.

In a currently preferred embodiment, a streptavidin/biotin linkage with a short aminocaproic acid chain conjugate 9 (see Reaction Scheme 3) is used in the

25   construction of the first linker between a binding partner and a nanoparticle, which is 10 nanometres in size. When a large size of nanoparticle such as a 20 nm bead is used, the first linker should preferably be designed much longer for consideration of easy regeneration on the sensor surface.

30   In a preferred embodiment, the present invention relates to a new design of optical biosensor-based competitive immunoassays (Figure 1) particularly surface plasmon resonance (SPR)-based immunoassays for small molecular weight haptens, such as therapeutic and abused drugs, steroids, thyroid hormones, metabolites and pollutants. This SPR-based immunoassay format method comprises the steps:

16

(a).   chemically immobilising hapten (A) or hapten conjugate onto the optical biosensor surface through a linker molecule (the second linker) with or without using a hapten attachment intermediate,

(b).   mixing a fixed concentration of binding partner (B)-(the first linker)-nanoparticle conjugate in buffer with each of a series of standard free solution or a sample hapten solution and incubating for a few minutes,

(c).   injecting the above mixture or the remaining binding partner (B) in equilibrium solution onto the hapten (A) biosensor surfaces, and measuring binding partner (B) responses,

(d).   injecting regeneration buffer, preferentially composed of sodium hydroxide and acetonitrile onto the biosensor surface to remove binding partner-(the first linker)-nanoparticle conjugate,

(e).   plotting concentrations of free hapten versus average response (RU) of binding partner -(the first linker)-nanoparticle conjugate to provide an assay standard curve from which determining the concentration of unknown sample hapten when using the same method.

It is preferred that steps (b), (c) and (d) are repeated three times or more for reproducibility.

With reference to Figure 1, the currently most preferred embodiment of the invention is now described. Design of "dual-linker" and "nanoparticle" is: (1) For hapten conjugate; Amino group---linker (10~30 atoms in length) (thiopropanoic acid with 1~3 aminocaproic acids)---small molecular hapten (progesterone); (2) For binding partner conjugate; antibody---long linker (anti-IgG)---gold nanoparticle (10 nanometre) (Reaction Scheme 3). Based on the above design, a rapid flow-through (BIAcore 2000) and sensitive immunoassay for small molecular hapten (progesterone, MW = 314.47) is achieved. The lowest detection limit (LDL) for the assay is around 8.6 pg/ml or 0.027 pM (2.7×10^{-14} M).

Reaction Scheme 3

(7)
BcapNHS

Monoclonal
anti-progesterone antibody

(8)

Streptavidin-Nanogold
particle (10 nm)

Linker-2

Antibody-(linker 2)-nanogold conjugate   (9)

5

This reaction scheme shows the structure of antibody-(linker-2)-nanogold conjugate (9) through the biotin/streptavidin linkage, and its preparation from commercial biotin agent BcapNHS (7) with monoclonal *anti*-progesterone

10   antibody (B) and followed by reaction with commercial streptavidin-nanogold particles (10 nm).

Based on the concept of a dual-linker combined with nanoparticle enhancement, the use of all other variations on the above methods by, for example, including various

15   nanoparticles in different sizes, different types, lengths, and molecular hybridisations of dual linkers fall within the scope of the present invention.

18

The invention also extends to kits comprising a first and a second moiety with their various attachments as described above in separate containers with or without instructions for their use.

5

The invention is illustrated by the following non-limiting examples.

BRIEF DESCRIPTION OF THE DRAWINGS

10   FIG. 1 shows a rapid optical biosensor-based immunoassay format using "dual-linker design with nanoparticle enhancement".

FIG. 2 shows the standard curve (RU percentage value to RU at 0 progesterone concentration versus concentration of progesterone in the range 0 to 1 µg/ml
15   measured according to the method of this invention.

FIG. 3 shows a sensorgram for monoclonal *anti*-progesterone antibody binding (25 µg/mL) followed by *anti*-IgG (secondary antibody) binding enhancement (800 µg/mL) and regeneration.

20

FIG. 4 shows low binding responses of monoclonal *anti*-progesterone antibody (♦) and sequential *anti*-IgG (secondary antibody) enhanced binding (■).

FIG. 5 shows a biotin/streptavidin mediated gold enhancement binding curve
25   [response (RU) verse antibody/gold volume ratio] for a pre-incubation format.

FIG. 6 shows a standard curve for a pre-incubation method of biotin/streptavidin mediated nanogold enhanced immunoassay.

30   FIG. 7 shows comparisons of three standard curves using a sequential binding format of biotin/streptavidin mediated nanogold enhanced immunoassay with three different concentrations of biotinylated monoclonal antibody [(♦) 2.5 µg/mL, (■) 7.5 µg/mL, and (▲) 15 µg/mL].

EXAMPLES

Syntheses of Hapten Derivatives

The structures of relevant compounds include:

5

Progesterone and progesterone analogue

(10)

Progesterone

(11)

11α-Hydroxyprogesterone

(12)

17α-Hydroxyprogesterone

(13)

21-Hydroxyprogesterone

Progesterone-4-positional derivatives


(14)

(16)

(15)

(17)

(18)
Testosterone

(19)
Cortisol

Epoxidation

Testosterone Epoxide

Cortisol Epoxide

1). KOH
2). HS⌒⌒OH

(20)
Testosterone 4-Acid

(21)
Cortisol 4-Acid

1). DCC/NHS
2). H₂N⌒⌒O⌒⌒O⌒⌒O⌒⌒NHBoc
3). Formic acid

(22)

(23)

(24)
19-Hydroxy-4-androsterone-3,17-dione

(25)
17α, 20β-Dihydroxy-4-pregnen-3-one

5

21

Estrogens and their 4-position functional derivatives

Estradiol
(26)

Estrone
(27)

Estriol
(28)

(29)

(30)

(31)

(32)

Catecholamines and their aromatic functional derivatives

Dopamine
(33)

Dopamine acid
(34)

Dopamine mercaptoundecanoic acid
(35)

nor-Epinephrine
(36)

nor-Epinephrine acid
(37)

Epinephrine
(38)

Epinephrine acid
(39)

5

EXAMPLE 1

Synthesis of Progesterone-PEG-NH₂ Derivative (6, Reaction Scheme 2)

5   4-mercapto-progesterone acid (4) (200 mg) was dissolved in DMF (dry, 1mL) and
     DCC (128 mg in 0.5 mL dry DMF) was added dropwise followed by NHS (71.3 mg
     in 0.5 mL dry DMF). The reaction was stirred in the dark overnight before filtering
     off the solid. Mono-PEG-Boc (458.2 mg) was dissolved in dry chloroform (1 mL)
     and added dropwise to the stirring ester solution. Triethylamine (0.5 mL) was then
10   added and the reaction stirred over the weekend in the dark. The solvent was removed
     in vacuo and the mixture was separated by column using 15:1 chloroform:methanol
     eluent to yield yellow oil for amine-protected product (progesterone-PEG-NHBoc).
     Yield: 169.8 mg (49%). R_f = 0.36 (15:1 chloroform:methanol). ^{1}H NMR (CDCl₃): δ:
     0.65 (s, 3H, 18-CH₃), 1.13 (s, 3H, 19-CH₃), 1.41 (s, 9H, Boc CH₃), 2.09 (s, 3H, 21-
15   CH₃), 2.89 (m, 6H, PEG), 3.57 (m, 14H, PEG). ^{13}C NMR (CDCl₃) δ: 13.7 (18-CH₃),
     18.4 (19-CH₃), 21.5 (11-CH₂), 23.2 (15-CH₂), 24.5 (16-CH₂), 25.3, 26.0 (S-CH₂),
     28.7 (Boc CH₃), 29.4, 30.0, 30.9, 31.0 (7-CH₂), 31.7 (21-CH₃), 32.4 (6-CH₂), 34.3,
     34.7 (1-CH₂), 34.9, 35.6, 36.7 (17-CH), 37.0, 38.9, 39.1 (12-CH₂), 41.7 (10-C), 44.2
     (13-C), 49.1, 54.5 (9-CH), 56.3 (14-CH), 63.7 (17-CH), 69.8 (PEG C-O), 70.0 (PEG
20   C-O), 70.5 (PEG C-O), 70.9 (PEG C-O), 129.0 (4-C), 156.3, 162.8, 171.4 (5-C),
     176.2 (carbonyl), 195.7 (3-C), 209.5 (20-C). ES-MS (MeOH): [M+H]$^+$ 722, [M+Na]$^+$
     744.

     The final free amine product or progesterone–PEG–NH₂ (6) can be easily synthesised
25   from the above Boc-protected compound by deprotection in formic acid (98% pure).

EXAMPLE 2

Synthesis of Progesterone–PEG–Biotin (17)

5   Progesterone–PEG–NH$_2$ (6) (160 mg) was dissolved in chloroform (1.5 mL, dried over molecular sieves 4A). Biotin active ester (113.8 mg in 1mL of dry DMF with warming) was added dropwise to the stirring progesterone–PEG–NH$_2$ solution. The solution was stirred in the dark for two hours before addition of triethylamine (0.5 mL) after which it was left stirring over the weekend. A solid initially forms but by
10   the end of the reaction it has gone. The solvent was removed in vacuo and then column separated using 10:1 chloroform:methanol and 5:1 chloroform:methanol eluent. Yield (17): 95.5mg (44%). R$_f$ = 0.70 (5:1 chloroform:methanol). ^{1}H NMR (CDCl$_3$): δ 0.70 (s, 3H, 18-CH$_3$), 1.25 (s, 3H, 19-CH$_3$), 1.72 (m, biotin), 1.80 (m, biotin), 2.14 (s, 3H, 21-CH$_3$), 2.95 (m, 5H, PEG), 3.20 (d, 1H, biotin), 3.37 (m, 2H,
15   PEG), 3.62 (m, 13H, PEG), 4.36 and 4.54 (d of t, 2H, biotin), 5.16 and 5.23 (d, 1H, biotin). ^{13}C NMR δ. ES-MS: 848.1 [M+H]$^+$, 870.1 [M+Na]$^+$.

EXAMPLE 3

20   *Preparation of 4-Progesterone Acid Derivative (14) and its ovalbumin conjugate*

A solution of ε-aminocaproic acid (44.4 mg (0.34 mM) in 200 μL of UHQ water) was added drop-wise to a solution of progesterone 18-atom linker-succinate active ester (*Steroids,* 67, 2002, 565-572) (83.8 mg (0.11 mM) in 2 mL of dry DMF). 0.5 mL of
25   dry DMF was used to wash out the ε-aminocaproic acid vial. The reaction was stirred over a weekend. The solvent was removed under vacuum and the resultant yellow-tinged oil reconstituted in 100 mL of chloroform and washed with 3x50 mL of distilled water. The solvent was removed under vacuum, and the resultant light brown oil was column separated using a 15:1, 10:1, 5:1, 1:1, 0:1 chloroform:methanol eluent
30   series. The resultant clear, colourless oil was washed with a diethyl ether, n-hexane, chloroform mixture to give waxy white solids (14). Yield: 68.1 mg (80%). R$_f$ = 0.77 (5:1 chloroform:methanol). ^{1}H NMR: δ 0.68 (s, 3H, 18-CH$_3$), 1.25 (s, 3H, 19-CH$_3$), 2.14 (s, 3H, 21-CH$_3$), 2.84 (t, 2H, J=6.8Hz, S-CH$_2$), 3.71 (d of t, 1H, J=14.7Hz, 6α-

24

H). ^{13}C NMR: δ 13.4 (18-C), 17.6, 18, 18.2 (19-C), 21.2 (11-C), 22.9 (15-C), 23.3,

24.3 (linker C), 25, 25.6, 26, 26.6, 29.2 (linker C), 29.8, 30.5, 30.8, 31.2, 31.8 (21-C),

31.9, 32.1 (6-C), 34.5, 34.7, 34.9, 35.7 (8-C), 36.8 (1-C), 36.9, 38.7, 39.6 (16-C),

39.8, 41.6 (10-C), 44 (13-C), 54.2 (9-C), 56, 63, 63.5 (17-C), 65.9, 171.5 (5-C), 173.8,

5   176.9, 196 (3-C), 209.5 (20-C), one overlapping peak. Analytical HPLC: 100% pure.

50°C, gradient of 30%B over 5min. then 30 – 80%B over 25min., A = 90:10 dH$_2$O:

MeOH, B = 90:10 MeOH:dH$_2$O, pH$_{A\&B}$ = 4.2, R$_t$ = 22.1 min. ES-MS: (MeOH, 40 V)

759 [M+H]$^+$, 781 [M+Na]$^+$.

10   A solution of DCC (17.7 mg in 250 µL dry DMF) was added drop-wise to a stirring

solution of above progesterone acid derivative 14 (50 mg in 2mL of dry DMF) and

250 µL of dry DMF used to wash out the vial. A solution of NHS (9.9 mg in 250 µL

of dry DMF) was then added drop-wise and a further 250 µL of dry DMF used to

wash. 0.5 mL of DMSO was then added to aid dissolution. The reaction was left

15   stirring in the dark overnight. Conjugation to OVA was then done as the same

procedure for other conjugates to produce conjugate (3) (*Steroids*, 67, 2002, 565-572).

EXAMPLE 4

20   *Synthesis of progesterone-4-mercaptopropionamide-ethylthiol (15)*

Progesterone-4-mercaptopropionyl succinate (*Steroids*, 67, 2002, 565-572) (100 mg,

0.194 mmol) was dissolved in dry DMF (1mL) and a solution of mercaptoethylamine

(44.8mg, 0.581mmol, in 0.5mL dry DMF) was added drop-wise followed by a further

25   0.5 mL of DMF to wash. The reaction was stirred overnight at room temperature.

Solid formed was filtered off and the filtrate solvent was removed in vacuo. The

resulting oil was washed with chloroform and the chloroform phase was column

separated using CHCl$_3$, 15:1 CHCl$_3$:MeOH, 10:1 CHCl$_3$: MeOH, 5:1 CHCl$_3$: MeOH

eluent to yield an oil. Yield: 17.1mg (18%). R$_f$ = 0.52 (15:1 chloroform:methanol). ^{1}H

30   NMR (CDCl$_3$): δ 0.70 (s, 3H, 18-CH$_3$), 1.26 (s, 3H, 19-CH$_3$), 2.15 (s, 3H, 21-CH$_3$),

2.45 (t, 1H, J = 7Hz), 2.53 (m, 3H), 2.88 (m, 4H, 2 x S-CH$_2$), 3.62 (m, 2H, CONH-

CH$_2$), 3.73 (d, 1H, J = 14Hz, 6α-H). ^{13}C NMR (CDCl$_3$): δ 13.4 (18-C), 18.1 (19-C),

20.8 (11-C), 23.0 (15-C), 24.3 (16-C), 25.0 (S-CH$_2$), 25.7 (S-CH$_2$), 30.5 (7-C), 31.5

(21-C), 32.1 (C-6), 34.0 (2-C), 34.2 (N-CH$_2$), 34.4 (1-C), 35.7 (8-C), 36.5 (CH$_2$CO), 38.7 (12-C), 41.6 (10-C), 43.8 (13-C), 54.2 (9-C), 55.8 (14-C), 63.5 (17-C), 129 (4-C), 172 (5-C), 175 (amide C = O), 195 (3-C), 209 (20-C). ES-MS: 476 Da [M-H]⁻.

5   **EXAMPLE 5**

Synthesis of Testosterone–PEG–NH$_2$ Derivative (22)

Testosterone (**18**) (807.5 mg, 2.8 mmol) was dissolved in methanol (45 ml). The
10   solution was stirred and cooled to 0 °C on ice, after which 10%w/v sodium hydroxide was added (3.4ml in distilled water), followed by 30% hydrogen peroxide (3.7ml). The reaction was then stirred at 0°C for four hours. The reaction solution was then raised to room temperature and the pH adjusted to 7.0 with 2 M acetic acid and the solvent removed in vacuo before drying. The resulting clear, colourless semi-solid
15   was partially dissolved in distilled water (30 ml) and then extracted with ethyl acetate (3 x 30ml). The organic phase was then washed with distilled water (1 x 30 ml) and dried over sodium sulphate. The solution was then decanted and the solvent removed and the sample dried to yield testosterone epoxide as a tacky solid. Yield: 810.0mg (96%). R$_f$ = unknown (no UV absorbance). IR (neat): 1055, 2362, 2945, 3584 cm⁻¹.
20   ¹H NMR: (CDCl$_3$) δ 0.76 (3H, s, 18-CH$_3$), 1.17 (3H, s, 19-CH$_3$), 2.98 (1H, s, 4-H), 3.4-3.7 (6ε- and 17α-H). ¹³C NMR: δ 11.1 (18-CH$_3$), 19.3 (19-CH$_3$), 21.1 (CH$_2$), 23.1 (CH$_2$), 26.1 (CH$_2$), 29.9 (CH$_2$), 33.1 (CH$_2$), 35.1 (CH), 36.5 (CH$_2$), 38.0 (CH$_2$), 43.0 (C), 46.6 (CH), 50.4 (CH), 60.7 (C), 62.6 (CH), 70.5 (C), 81.3 (CH), 207.5 (3-carbonyl). ES-MS: (MeOH, -20V): 353.1 [M+MeOH+H$_2$O-H]⁻. Mp = 100-102°C.
25   Lit mp: 156-157°C. HPLC: 60% MeOH, 100% purity, R$_t$ = 9.83min. λ$_{max}$ = 203 nm.

Testosterone epoxide (517.5 mg, 1.7 mmol) was dissolved in ethanol (5 ml, dried over molecular sieves). In a 20ml flask, 25%w/v potassium hydroxide (0.8 ml in distilled water) was added with 3-mercaptopropionic acid (244 µl, 2.8 mmol). The epoxide
30   solution was then added slowly to the stirring MPA solution and the sample immediately placed under nitrogen and stirred for four hours. Distilled water (30 ml) was then added which immediately precipitated a white solid. The sample was then extracted with diethyl ether (3 x 30 ml) and the aqueous phase was pH adjusted to 1.5

with 1M HCl and further extracted with ethyl acetate (3 x 30 ml). The combined organic phase was then dried over sodium sulphate and the solvent removed and the sample dried to yield testosterone acid (20) as a white solid. Yield: 642.3 mg (96%). R_f = 0.25 (15:1 chloroform: methanol). IR (neat): 1708, 2288, 2935cm^{-1}. ^{1}H NMR: δ

0.77 (18-CH$_3$), 1.16 (19-CH$_3$), 2.52 and 2.69 (1H each, t, J = 7.3Hz, CH$_2$-COOH), 2.78 and 2.99 (1H each, m, CH$_2$-S), 3.67 (1H, t, J = 11.2Hz, 6α-H), 4.12 (1H, q, J = 9.5Hz, 17α-H). ^{13}C NMR: δ 11.1 (18-CH$_3$), 19.0 (19-CH$_3$), 19.6 (CH$_2$), 23.6, 26.0 (S-CH$_2$), 29.8 (CH$_2$), 29.9 (16-CH$_2$), 32.4 (12-CH$_2$), 35.0 (8-CH), 36.2 (1-CH$_2$), 37.2 (C), 38.2 (CH$_2$), 42.9 (C), 46.5 (CH), 50.6 (CH), 61.0 (CH$_2$), 62.6 (CH), 70.4 (C), 81.5 (CH), 175.7 (acid), 207.2 (3-carbonyl). ES-MS (40V, MeOH): 393.3 [M+H]$^+$, 415.0 [M+Na]$^+$. Mp = 112-116°C / 132-136°C. Lit mp: 156-159 / 179-181°C. HPLC: 60% methanol, R_t = 4.47 min., % Purity = 96%.

Testosterone acid (20) (642.3 mg, 1.637 mmol) was dissolved in dry DMF (5 ml, dried over molecular sieves). DCC (416.4 mg, 2.128 mmol, in 1ml dry DMF) was added dropwise to the stirring steroid solution, followed by NHS (232.1 mg, 2.128 mmol, in 1ml of dry DMF) was also added dropwise. The solution was stirred at room temperature for 48 hours in the dark. The white solid formed was filtered off and washed thoroughly with dry DMF. The filtrate had solvent removed and sample dried in vacuo. The sample was then column separated using chloroform and 15:1 chloroform: methanol as eluent yielding testosterone succinimide ester as a white semi-solid. Yield: 783.0 mg (98%). R_f = 0.41 (15:1 chloroform: methanol). IR (neat): 1207, 1630, 1737, 2931cm^{-1}. ^{1}H NMR: δ 0.76 (3H, s, 18-CH$_3$), 1.16 (3H, s, 19-CH$_3$), 2.85 (4H, s, NHS protons), 3.64 (2H, m, 6α-H and 17α-H). ^{13}C NMR: δ 11.1 (18-CH$_3$), 18.9 (19-CH$_3$), 21.1 (CH$_2$), 23.4 (CH$_2$), 25.1 (CH$_2$) 25.6 (NHS CH$_2$), 29.6 (CH$_2$), 29.9 (CH$_2$), 32.4 (CH$_2$), 35.1 (CH), 36.4 (CH$_2$), 37.2 (C), 41.5 (CH$_2$), 43.0 (C), 46.5 (CH), 50.7 (CH), 54.4 (CH$_2$), 62.6 (CH), 70.3 (C), 81.5 (CH), 167.1 (amide), 169.2 (NHS carbonyl), 207.2 (3-carbonyl). ES-MS: (MeOH 40V): 490.3 [M+H]$^+$. Lit mp: 154-156°C. HPLC: 5% MeOH, R_t = 2.03min, λ_{max} = 259nm, % purity = 100%.

Testosterone succinimide ester (658.9 mg, 1.347 mmol) was dissolved in dry DMF (3.5 ml) and stirred whilst a solution of mono-Boc-PEG was added dropwise (646.2 mg, 2.021 mmol, in 1.5 ml of dry chloroform) followed by a chloroform rinse (250

μl). Triethylamine (750 μl) was then added to the stirring solution and the solution stirred at room temperature in the dark for 60 hours. The solvent was then removed and sample dried *in vacuo* and the sample column separated using chloroform, 15:1 chloroform: methanol and 10:1 chloroform: methanol as eluent to yield testosterone-PEG-Boc as an orange oil. Yield 724.5 mg (77%). R_f = 0.50 (10:1 CHCl$_3$: MeOH). IR (neat) 1532, 1659, 2931, 3335cm^{-1}. ^{1}H NMR: δ 0.80 (3H, s, 18-CH$_3$), 1.24 (3H, s, 19-CH$_3$), 1.43 (9H, s, Boc methyls), 1.77 (4H, m, O-CH$_2$-CH$_2$-CH$_2$-NH), 2.58 (2H, t, J = 7.1Hz, CH$_2$-CONH), 2.96 (2H, t, J = 7.7Hz, S-CH$_2$), 3.20 (2H, d of t, J_d = 6.7Hz, CH$_2$-CO-NH-CH$_2$), 3.41 (2H, d of t, J_d = 5.9Hz, J_t = 5.8Hz CH$_2$-NH-CO), 3.52-3.66 (12H, m, O-CH$_2$). ^{13}C NMR: δ 11.1 (18-CH$_3$), 18.9 (19-CH$_3$), 21.1 (CH$_2$), 23.4 (CH$_2$), 25.1 (CH$_2$), 28.4 and 28.9 (O-CH$_2$-CH$_2$-CH$_2$-NH) 29.0 (CH$_2$), 29.6 (S-CH$_2$), 30.1 (CH$_2$), 34.1 and 35.7 (CH$_2$-CO-NH-CH$_2$), 35.3 (CH), 36.5 (CH$_2$), 37.6 (C), 38.3 (C), 42.8 (CH$_2$), 46.5 (CH), 50.4 (CH), 54.4 (CH$_2$), 63.0 (CH), 70.1 (cluster, CH$_2$-O) 70.4 (C), 81.1 (17-CH), 156.1 (Boc terminal amide), 168.8 (steroid terminal amide), 195.6 (3-carbonyl). ES-MS: (MeOH 40V): 695.6 [M+H]$^+$, 717.6 [M+Na]$^+$, 815.5 [M+2CH$_3$COOH+H]$^+$, 837.5 [M+2CH$_3$COOH+Na]$^+$. Analytical HPLC: MeOH mobile phase, 1 ml/min. 95% pure, R_t = 2.03 min, 206 nm.

The final free amine product or testosterone–PEG–NH$_2$ (22) can be easily synthesised from the above Boc-protected compound by deprotection in formic acid (98% pure).

EXAMPLE 6

Synthesis of Cortisol–PEG–NH$_2$ Derivative (23)

Cortisol (19) (362.5 mg, 1.0 mmol) was partially dissolved in methanol (13 ml) and ethanol (5 ml) and chilled to 0 °C. Sodium hydroxide solution (10%w/v in distilled water, 1 ml) was added followed by 30% hydrogen peroxide solution (400 μl). The reaction was kept stirring at 0 °C on ice for three hours. The reaction mixture was then raised to room temperature; any remaining solid was filtered off using a sintered glass funnel. The filtrate pH was carefully adjusted to 7.0 using acetic acid and the resulting solution dried *in vacuo* to yield a clear, colourless oil. This sample was then constituted in distilled water (30 ml) and extracted with 3 x 30 ml of ethyl acetate.

The organic phase was then washed with 1 x 30 ml of distilled water and the organic phase dried over sodium sulphate. The supernatant was then passed through a bed of calcined alumina (~10 g) and the solvent removed and sample dried *in vacuo* to yield **cortisol epoxide** as clear, colourless oil. The product was then column separated

5   using 1:1 ethyl acetate: *n*-hexane to yield as an analytical sample. Yield: 86.6 mg (23%). R_f = 0.36 (1:1 ethyl acetate: *n*-hexane). IR (KBr disc): 1450, 1701, 1724, 2369, 2928, 3449cm^{-1}. ^{1}H NMR (δ): 1.14 (3H, s, 18-CH$_3$), 1.36 (3H, s, 19-CH$_3$), 3.03 and 3.06 (1H, s, 4-H, β and α respectively), 4.30, 4.40 (1H each, d, J = 3.7Hz, 21-H). ^{13}C NMR (δ): 15.9 (18-CH$_3$), 20.0, 21.1, 22.2, 25.8, 28.3, 28.6, 29.0, 29.4, 30.4 (19-

10 CH$_3$), 32.9, 35.2, 35.3, 40.6, 52.2, 62.8, 62.9, 68.0, 68.6, 206.5, 218.9. ESMS (-40V, MeOH): 363.2 [M+H$_2$O-H]$^+$. Melting point: 157-160°C β epimer. 166-169 °C α epimer. Lit. Mp: β 147-148°C, α 167-168°C. HPLC: 1ml/min. 60% MeOH, 100% purity, R_t = 4.60 and 4.85min for the two epimers, λ_{max} = 204nm.

15 Cortisol epoxide (586.8 mg, 1.559 mmol) was dissolved in ethanol (dried over molecular sieves, 5ml). A solution of potassium hydroxide (25%w/v in distilled water, 730µl) was added to a small flask and stirred whilst 3-mercaptopropionic acid (224 µl) was added. The stirring solution then had the epoxide solution added dropwise and was immediately placed under nitrogen and stirred at room temperature for four

20 hours. Distilled water (30 ml) was added. The aqueous phase was then extracted with diethyl ether (3 x 30 ml) before adjusting the pH of the aqueous phase to 1.5 with 1M HCl. The aqueous phase was then extracted with 3 x 30ml of ethyl acetate. The organic phase was then dried over sodium sulphate and the liquor decanted and solvent removed and sample dried *in vacuo*. The sample was then column separated

25 using chloroform, 15:1 chloroform: methanol and methanol eluent. The sample was then dried to yield 4-mercapto-cortisol acid (21) as clear, colourless oil. Yield: 479.9 mg (66%). R_f = 0.42 (5:1 chloroform: methanol). IR (neat): 1108, 1657, 2360, and 2920. ^{1}H NMR: δ 0.89 (3H, s, 18-CH$_3$), 1.21 (1H, t, J = 7.0Hz), 1.47 (3H, s, 19-CH$_3$), 2.47 (2H, t, J = 7.0Hz, CH$_2$-COOH), 2.84 (2H, t, J = 7.1Hz, S-CH$_2$), 3.66 (1H, q, J =

30 7.0Hz), 4.28 (1H, d, J = 19.4Hz, 21-H), 4.66 (1H, d, J = 19.4Hz, 21-H). ^{13}C NMR: δ, 21.4, 22.1, 26.0, 26.2 (S-CH$_2$), 33.1 (19-CH$_3$), 35.4, 38.1, 38.4, 39.5, 46.3, 51.7, 53.3, 54.1, 56.1, 60.2, 71.1, 72.1, 93.2, 130.5, 179.6 (carboxylic acid), 182.9 (17-C), 200.8 (20-carbonyl), 216.9 (3-carbonyl). ES-MS (40V, MeOH): 466.1 [M+H]$^+$, 488.0

[M+Na]$^+$. Mp: 132-136 °C. Lit. Mp: 177-178°C. HPLC: 1 ml/min. 60%v/v methanol. R_t = 1.95min. % Purity = 100%.

Cortisol acid (21) (479.9 mg, 1.029 mmol) was dissolved in dry DMF (4 ml, dried over molecular sieves) and DCC (275.9 mg, 1.337 mmol, in 1 ml dry DMF) was added dropwise to the stirring steroid solution. This was followed by NHS (153.9 mg, 1.337 mmol, in 1 ml dry DMF) dropwisely. The reaction was stirred overnight at room temperature in the dark. The white solid formed was then filtered off and washed with dry DMF and the filtrate solvent removed *in vacuo*. The sample was then column separated using chloroform, 15:1 chloroform: methanol, 10:1 chloroform: methanol to yield cortisol succinimide ester as a pale yellow semi-solid. Yield: 486.9mg (84%). R_f = 0.69 (5:1 chloroform: methanol). IR (KBr disc): 1078, 1655, 1736, 2928cm^{-1}. ^{1}H NMR: δ 0.90 (3H, s, 18-CH$_3$), 1.50 (19-CH$_3$), 2.64 (2H, t, J = 6.8Hz), 2.83 (2H, t, J = 6.5Hz), 2.88 (4H, d, J = 1.2 Hz, NHS protons), 4.29 (1H, s, broad, 21-H). ^{13}C NMR: δ 16.9 (18-CH$_3$), 21.8, 23.8, 25.1, 25.8 (S-CH$_2$), 28.1, 30.6, 31.9, 33.1 (19-CH$_3$), 33.7, 34.0, 34.4, 39.4, 42.3, 47.7, 48.7, 52.0, 56.4, 68.0, 89.6, 125.6, 158.4, 167.7, 171.0, 179.6 (17-C), 196.4 (20-carbonyl), 206.8 (3-carbonyl). ES-MS: (40V, MeOH) 695.7 [M+ DMF + 2H$_2$O + Na]$^+$. Mp: 139-142°C. HPLC: 30% methanol, R_t = 1.86min, % Purity = 90%.

Cortisol succinimide ester (486.9 mg, 0.864 mmol) was dissolved in dry DMF (3.5 ml, dried over molecular sieves). To the stirring steroid solution, was added mono-Boc PEG (416.0 mg, 1.296 mmol, in 1.2 5ml of dry chloroform (dried over molecular sieves) dropwise, with an additional 2 x 250µl of dry chloroform used to wash. The stirring solution had dry triethylamine added (750 µl, dried over molecular sieves). The reaction was then stirred at room temperature in the dark for 60 hours. After 12 hours, another 1 ml of dry DMF was added to aid solubility. The reaction was then stopped and solvent removed and sample dried *in vacuo* before column separation using chloroform, 15:1 chloroform: methanol and 10:1 chloroform: methanol as eluent, yielding cortisol-PEG-Boc compound as an orange oily solid. Yield: 413.6 mg (62%). R_f = 0.32 (10:1 chloroform: methanol). IR (KBr disc) 1707, 2930, 3437 cm^{-1}. ^{1}H NMR: δ 0.90 (3H, s, 18-CH$_3$), 1.43 (9H, s, Boc methyls), 1.50 (3H, s, 19-CH$_3$), 1.71-1.78 (6H, m, 4H from O-CH$_2$-CH$_2$-CH$_2$-NH, 2H from steroid fine structure), 2.60 (2H, m, CH$_2$-COOH), 2.82 (2H, m, CH$_2$-S), 3.11 (2H, t, J = 6.6Hz, CH$_2$-CO-

NH-CH$_2$), 3.26 (2H, m, CH$_2$-NH-CO), 3.50-3.70 (14H, m, 12H from O-CH$_2$, 2H from

steroid fine structure). ^{13}C NMR: δ 16.8 (18-CH$_3$), 21.5, 22.0, 25.6, 27.7, 27.9, 28.1,

28.3 and 28.6 (O-CH$_2$-CH$_2$-CH$_2$-NH), 29.5 (S-CH$_2$), 29.8 (CH$_2$), 30.3, 33.8 (19-CH$_3$),

34.5, 35.0, 37.9 (C), 42.4 (CH$_2$), 47.9, 48.1, 48.4, 48.6, 52.2, 52.4, 56.7, 69.0, 69.1,

5   69.8, 70.1 and 70.3 and 70.6 (CH$_2$-O), 79.0, 89.6, 126.1, 126.4, 157.3 (Boc terminal

amide), 172.7 (steroid terminal amide), 178.9, 196.5 (3-carbonyl), 206.0 (20-

carbonyl). ES-MS: m/z (MeOH, 40V) 385.4 [M+2H]$^{2+}$. Mp: 32-33°C. HPLC: Purity:

99%. MeOH mobile phase, 1ml/min. R$_t$ = 1.92min, λ$_{max}$ = 206 nm.

10   The final free amine product or cortisol–PEG–NH$_2$ (23) can be easily synthesised

from the above Boc-protected compound by deprotection in formic acid (98% pure).

EXAMPLE 7

15   *4-Mercaptol-Estradiol Acid (29)*

4-bromoestradiol (200 mg) was dissolved in dry methanol (20 mL). Methanolic

potassium hydroxide (20 mL, 7.8 mgmL^{-1}) was added followed by 3-mercapto-

propionic acid (550 μL). The solution was refluxed under dry conditions for 24 hours

20   in the dark. The solvent was removed and the sample reconstituted in distilled water

(50 mL). The aqueous phase was washed with ethyl acetate (2 x 25 mL, 1 x 50 mL).

The aqueous phase had its pH adjusted to 2.5, which crashed a white solid out of

solution. The solid was separated by centrifugation and washed three times with water

and then dried to yield a white solid 29 (103.4 mg, 46%). mp 78-84 °C; R$_f$ = 0.46

25   (ethyl acetate); ^{1}H NMR 0.81 (3H, s, 18-CH$_3$), 1.38-2.3 (m, estradiol fine structure),

2.75 (3H, t, J= 4.6, 17-CH), 2.81 (2H, t, J= 4.5, S-CH$_2$), 6.89 (1H, d, J= 6.3, 2-H),

7.22 (1H, d, J = 6.7Hz, 3-H); ^{13}C NMR 10.4 (18-CH$_3$), 14.2, 21.2, 21.4, 22.8, 23.1,

24.0, 25.4, 26.8, 29.1 (S-CH$_2$), 29.8, 30.2, 31.0, 33.8, 34.2, 37.1, 50.9 (17-CH), 74.6,

90.5, 171.5 (3-C), 194 (COOH); ES-MS m/z 399.1 [M+H]$^+$, 406.8 [M+OMe]$^-$.

30

EXAMPLE 8

4-Estradiol–PEG –NH₂ (30)

5   4-Estradiol acid (29) (80 mg, 0.201 mmol) was dissolved in dry DMF (1 mL) and
DCC (53.9 mg in 0.5 mL of dry DMF, 0.2613 mmol) was added dropwise to the
vigorously stirring solution followed by NHS (30.1 mg in 0.5 mL of dry DMF, 0.2613
mmol). The solution was stirred overnight at room temperature in the dark. A white
solid formed within 30min of addition. The solid was filtered off and the solvent
10   removed. The sample was then column separated using 15:1 chloroform:methanol,
10:1 chloroform:methanol and 5:1 chloroform:methanol. The pure product (4-
estradiol succinimidyl ester) was isolated as a white solid (44.0 mg, 44%). Mp = 149-
156 °C. R_f = 0.48 (10:1 chloroform methanol). ^{1}H NMR: δ 0.82 (3H, s, 18-CH₃),
1.05-2 (m, estradiol fine structure), 2.73 (t, 17 CH), 2.90 (2H, t), 2.97 (4H, s, NHS
15   protons), 8.03 (2H, s, aromatic ring); ^{13}C NMR 25.2 (CH₂), 25.7 (CH₂), 25.9 (CH₂),
27.3 (CH₂), 29.9 (S-CH₂), 30.0 (CH₂), 31.5 (18-CH₃), 31.9 (CH₂), 32.7 (CH₂), 33.5
(CH₂), 34.0 (CH₂), 34.3 (CH₂), 34.5 (succinate CO), 35.0 (succinate CO), 37.0 (CH),
49.8 (CH), 51.0 (17-CH), 52.2 (CH), 154.1 (C), 158.0 (C), 163.3 (CH), 169.2 (C),
172.5 (CH), 175.2 (3-C), 175.4 (ester); ES-MS *m/z* 471.6 [M+H]⁺.
20

The above synthesised 4-estradiol succinimidyl ester (50 mg, 0.106 mmol) was
dissolved in dry DMF (1 mL) and stirred rapidly whilst mono-Boc protected PEG
(220) (102.6 mg, 0.372 mmol in chloroform, 0.5 mL) was added drop-wise followed
by triethylamine (0.25 mL). The solution was then stirred over the weekend at room
25   temperature in the dark. The solvent was then removed and the resulting oil column
separated   using   15:1   chloroform:methanol,   10:1   chloroform:methanol,   5:1
chloroform:methanol eluent sequence, yielding pure compound [4-estradiol-PEG
(220)-NHBoc] as a clear, colourless oil (62.3 mg, 0.098 mmol, 93% yield). R_f = 0.36
(10:1 chloroform: methanol). ^{1}H NMR: δ 1.24 (2H, t, *J* = 7.0), 1.44 (9H, s, Boc CH₃),
30   1.79 (5H, m), 2.59 (2H, t, *J* = 7.4), 2.74 (3H, t, *J*= 6.2), 2.98 (5H, m), 3.37 (2H, m),
3.60 (14H, m), 5.06 (1H, s), 6.82 (1H, s, aromatic estradiol); ^{13}C NMR: 18.4 (estradiol
CH₃), 26.4, 27.2, 28.5, 28.7 (Boc CH₃), 29.7, 33.2, 33.3, 33.8, 34.0, 34.3, 34.6, 36.2,
36.5, 38.0, 38.4, 50.6, 52.0, 58.4, 69.4, 69.9 (PEG C-O) 70.1 (PEG C-O), 70.2 (PEG

C-O), 70.5 (PEG C-O), 70.5 (PEG C-O), 79.3 (17-CH), 100.3, 102.8, 109.8, 127.6, 139.1, 156.3, 171.4 (CH), 171.7, 175.1 (Boc carbonyl), 181.1 (mercaptol-propionate carbonyl); ES-MS (MeOH, 45V) 535.4 $[M-Boc+H]^+$, 557.4 $[M-Boc+Na]^+$, 652.4 $[M+NH_4]^+$, 670.4 $[M+H_2O+NH_4]^+$.

The final free amine product or 4-estradiol–PEG–NH$_2$ (30) can be easily synthesised from the above Boc-protected compound by deprotection in formic acid (98% pure).

EXAMPLE 9

4-Estradiol–PEG (900)– NH$_2$ (31)

Polyethylene glycol (900) [O, O'-Bis-(2-aminopropyl)polypropylene glycol-block-polyethylene glycol-block polypropylene glycol, Fluka 14527] (2 g, approx. 2.22 mmol) was dissolved in dry methanol (20 mL) and dry triethylamine (1 mL) was then added. Boc reagent (0.4856 g, 2.22 mmol) was dissolved in dry methanol (10 mL) and added drop-wise to the above rapidly stirring PEG solution over ~ 20 min using a syringe and septum. The solution was then left to rapidly stir overnight at room temperature. The solvent was then removed and the sample was separated by a column using 32:1:1, 32:2:1, 32:4:1, 16:4:1 dichloromethane:methanol:acetic acid eluent to yield mono-protected PEG (900) as a clear colourless semi-solid (911.4 mg, 41% yield). R$_f$ = 0.53 (32:2:1 dichloromethane:methanol:acetic acid). ^{1}H NMR: δ 1.13 (s, 8H), 1.27 (s, 3H), 1.44 (s, 9H, Boc CH$_3$), 2.00 (s, 6H), 3.45 (s, 7H), 3.65 (s, 65H, ethylene protons); ^{13}C NMR: 15.0, 15.3, 15.4, 16.1, 16.8, 16.9, 17.0, 17.9, 18.8, 22.5, 28.4 (Boc CH$_3$), 46.6, 47.1, 47.2, 48.4, 70.3 (cluster), 72.5, 72.6, 74.4, 74.9, 75.2, 75.5, 76.2, 155.5, 176.1 (Boc-carbonyl). ES-MS: (MeOH 40V) multiple peaks corresponding to different n-values of the PEG chain.

4-Estradiol succinimidyl ester (50 mg, 0.106 mmol) was dissolved in dry DMF (1 mL) and stirred rapidly whilst mono-Boc PEG (900) (371.7 mg, approx. 0.372 mmol dissolved in 5:1 chloroform:methanol, 3 mL) was added drop-wise followed by triethylamine (0.5 mL). The solution was stirred at room temperature over the weekend in the dark. The solvent was then removed and the resulting orange oil

column separated using 15:1 chloroform: methanol, 10:1 chloroform: methanol, 5:1 chloroform: methanol eluent to yield pure protected product [4-estradiol-PEG (900)-NHBoc] as a clear, colourless oil (39.5 mg, 0.029 mmol, 27% yield). R_f = 0.73 (5:1 chloroform:methanol). ^{1}H NMR: δ 1.14 (14H, m), 1.44 (9H, s, Boc CH$_3$), 2.58 (2H, t,

5   J= 7.1), 2.73 (3H, t, J = 7.0), 2.97 (6H, m), 3.47 (m), 4.91 (1H, s), 6.75 (1H, t of d, J = 34.9, J = 7.9); ^{13}C NMR: 16.7, 17.1, 17.6, 18.0, 28.5 (Boc CH$_3$), 29.7, 34.1, 34.3, 36.2, 45.1, 45.5, 70.6 (PEG C-O), 71.9 (PEG C-O), 72.1, 72.4, 72.6, 73.4, 74.0, 74.5, 75.1, 75.3, 75.6, 75.9, 126, 128, 130, 155.7, 164, 170.8, 174.4. ES-MS: (MeOH, 40V) multiple peaks from range of PEG chain n-values.

10

The synthesis of final 4-estradiol–PEG (900)–NH$_2$ (31) is carried out in the same procedure as for 4-estradiol–PEG–NH$_2$ (30) in formic acid (98% pure).

EXAMPLE 10

15

4-Mercapto-Estrone Acid (32)

Estrone (27) (400 mg, 1.48 mmol) was dissolved in dry ethanol (10 mL) and acetone (10 mL). *N*-bromosuccinimide (263.3 mg, 1.48 mmol) was added to the vigorously

20   stirring solution and the solution stirred at room temperature for 24 hours. The white solid formed was filtered off and washed with ethanol (174.5 mg, 34%). Removal of the filtrate solvent and recrystalisation of the resultant solid as **4-bromoestrone** provided 43% of yield. Mp 254 °C (literature 281-282 °C); R_f = 0.23 (4:1 petroleum spirit 60-80 °C: ethyl acetate); ^{1}H NMR 0.90 (3H, s), 0.90 (1H, s), 1.26 – 2.96 (m),

25   5.37 (1H, s), 6.86 (1H, d, J= 8.6Hz), 7.18 (1H, d, J= 8.6Hz); ES-MS *m/z*.

4-bromoestrone (150 mg, 0.43 mmol) was dissolved in dry methanol (20 mL) and potassium hydroxide (15 mL, 23.4 mgmL^{-1} in dry methanol) was added whilst stirring, followed by 3-mercaptopropionic acid (424.8 µL) and refluxed under dry

30   conditions for 24 hours. The sample was then cooled and solvent removed. The sample was reconstituted in distilled water (25 mL) and extracted with ethyl acetate (2 x 12.5 mL, 1 x 25 mL). The solvent was removed and the sample recrystallized from chloroform to provide pure 4-mercapto-estrone acid (32) (42.6 mg, 27%): Mp 108-

112 °C; R_f = 0.12 (15:1 chloroform:methanol); ^{1}H NMR 0.87 (3H, s, 18-CH$_3$), 1.23-3

(17H, m, estrone fine structure), 3.04 (2H, t, J = 1.9, S-CH$_2$), 6.50 (1H, d J = 8.7, C-

2), 6.80 (1H, d, J = 9.0, C-1); ^{13}C NMR 17.5, 23.4, 25.5, 28, 30, 30.7, 34.5, 35, 39.5,

41.5, 42.3, 48.1, 54.2, 117, 118.8, 119.2, 123.5, 125.4, 129, 159, 178.4; ES-MS: m/z

5   374.5 [M+H]$^+$, 397.5 [M+Na]$^+$.

EXAMPLE 11

Dopamine 5-Mercaptopropanoic Acid (34)

10

Dopamine (33) (400 mg, 2.12 mmol) was dissolved in dry methanol (30 mL) and *N*-

hydroxysuccinimide (375.2 mg, 2.12 mmol) was added and the solution stirred at

room temperature in the dark for 24 hours. The solution then had the solvent removed

and was reconstituted in distilled water (50 mL) and washed with chloroform (2 x 25

15   mL, 1 x 50 mL) and the solvent removed from the aqueous phase. The sample was

reconstituted in methanol and decoloured thoroughly with activated charcoal. The

solvent was then removed to yield 5-bromo-dopamine as an off-white semi-solid

(239.5 mg, 49%). R_f = 0.54 (40:1 methanol:acetic acid), ^{1}H NMR 2.94 (2H, t, J = 7.2

NH$_2$-CH$_2$), 3.17 (2H, t, J = 6.9 Ar-CH$_2$), 6.74 (1H, m, 2-CH), 6.92 (1H, m, 5-CH); ^{13}C

20   NMR 31.0 (Ar-C), 31.85 (Ar-C), 39.4 (C-NH$_2$), 40.5 (C-NH$_2$), 115.7 (2-C), 116.5 (5-

C), 116.6 (6-C), 117.0 (3-C), 118.0 (4-C), 124.2 (1-C); ES-MS m/z 233 isotope

pattern [M+H]$^+$.

The above synthesised 5-bromo-dopamine (100 mg, 0.429 mmol) was dissolved in

25   dry methanol (5 mL) and methanolic KOH was added (11.8 mgmL^{-1}, 5 mL) with

vigorous stirring. 3-Mercaptopropionic acid (113.7 µL) was added and the reaction

refluxed under dry conditions for 24 hours. The solvent was then removed and the

resultant semi-solid constituted in distilled water (25 mL). The aqueous phase was

washed with ethyl acetate (2 x 12.5 mL, 1 x 25 mL) and the aqueous phase acidified

30   to pH = 1. The solvent was removed from the aqueous phase to yield a yellow-white

semi-solid (250.6 mg), which was then passed through a short silica column using

40:1 methanol:acetic acid eluent to yield pure product 34 as a white solid (44.1 mg,

40% yield). Mp= 292-298 °C, R_f = 0.55 (40:1 methanol: acetic acid), ^{1}H NMR: δ

2.44 (2H, t, J = 9.5, CH_2-COOH), 2.77 (2H, t, J = 9.7, CH_2-S), 2.54-2.88 (2H, m, CH_2-Ar), 3.19-3.57 (m, CH_2-NH_2); ^{13}C NMR: 23.0 (S-CH_2), 23.7 (CH_2-COOH), 34.7 (CH_2-Ar), 36.9 (CH_2-NH_2), 117.3 (C-2, C-5), 122.2 (C-1), 125.4 (C-6), 136.8 (C-3), 143.2 (C-4), 170.3 (acid); ES-MS: m/z 255.2 [M-H]⁻, 279.2 [M+Na-2H]⁻, 211.9 [M-

5   catechol chain – H]⁺.

EXAMPLE 12

Catecholamine-Thioether Synthesis by Electrolysis

10

Dopamine 5-Mercaptopropanoic Acid (34)

Dopamine (33) (30 mg, 0.158 mmol) was dissolved in 80ml of 0.1M HCl. The solution had a voltage of 2V applied across it between two pressed graphite bar electrodes and was vigorously stirred to prevent air bubble formation. The electrolysis

15   was conducted over 2.5-3 hours and the initially colourless solution soon turned bright yellow and then bright orange. The formation of the coloured o-quinone was monitored by HPLC. Once maximum o-quinone formation had occurred, the solution then had 10%v/v 3-mercaptopropionic acid (412.6 µl, 0.473 mmol) added rapidly with vigorous stirring. The reaction was monitored and was left overnight as a

20   precaution to ensure maximum product (34) formation. Yield: 14 mg (0.0545 mmol, 34%). Mp: decomposes. ^{1}H NMR: δ D_2O: 2.49 (2H, t, J = 7.9Hz, CH_2-S), 2.72 (2H, t, J = 9.2Hz, CH_2-N), 2.95 (2H, t, J = 7Hz, CH_2-Ar), 3.07 (2H, t, J = 9.2Hz, CH_2-COOH), 6.68 (1H, s, 6-H), 6.77 (1H, s, 2-H). ^{13}C NMR: δ D_2O 28.6 (CH_2-S), 32.0 (CH_2-COOH), 34.1 (CH_2-Ar), 40.6 (CH_2-NH_2), 116.5 (2-C), 120.5 (5-C), 125.3 (6-

25   C), 129.3 (1-C), 144 (3-C or 4-C), 144.5 (3-C or 4-C). ES-MS: 1:1 AcCN: H_2O 5V 258.9 [M+H]⁺.

Dopamine 5-Mercaptoundecanoic Acid (35)

Dopamine (33) (30 mg, 0.158 mmol) was dissolved in 0.2M HCl total 50%v/v

30   acetonitrile and electrolysed at 2V with vigorous stirring for 2.5hrs. The ortho-quinone formation was followed by HPLC and the current was observed to drop from 20mA to 9mA within 30min period. 11-mercaptoundecanoic acid (103.7 mg, 0.475 mmol, in 6 ml of 50%v/v acetonitrile 0.2 M HCl total) was added rapidly to the vigorously stirring solution. Colour was observed to fade gradually until by 30 min.

there is no significant colour left. Yield: 9.2 mg (0.025 mmol) 16%. ^{1}H NMR δ 1.21 (10H, main chain CH_2 of UDA), 1.36 (2H, UDA), 1.56 (4H, UDA), 2.36 (2H, CH_2-S), 2.87 (2H, CH_2-N), 2.88 (2H, CH_2-Ar), 3.22 (2H, CH_2-COOH), 6.78 (1H, Ar 5 or 6-H), 6.88 (1H, Ar 2-H). ^{13}C NMR: δ 24.3, 28.3 (CH_2S), 32.1 (CH_2-COOH), 33.3,

5   33.9 (CH_2-Ar), 40.6 (CH_2-NH_2), 115.5 (2-C), 122.6 (5-C), 123.8 (6-C), 129.3(1-C), 143.0 (3-C or 4-C), 144.4 (3-C or 4-C), 179.1 (acid). ES-MS: (CH_3CN/H_2O) (370.6 M+H)$^+$.

Nor-Epinephrine Mercaptopropanoic Acid (37)

10   Nor-epinephrine bitartrate (36) (40 mg, 0.125 mmol) was dissolved in 80 ml of 0.1M HCl and electrolysed at 2V until maximum conversion to ortho-quinone was observed (usually two hours). 3-Mercaptopropionic acid (327.5 µl of 1/10 solution in 0.1 M HCl, 0.375 mmol) was added with rapid stirring and the bright orange colour left the solution immediately. The reaction was stirred vigorously overnight. Yield: (14.0 mg,

15   0.0512 mmol, 41%) ^{1}H NMR: δ (D_2O) 2.67 (2H, t, J = 7.2Hz, S-CH_2), 3.15 (2H, m, CH_2-N), 3.27 (2H, m, CH_2-COOH), 4.55 (1H, s, CH-OH), 6.91 (1H, s, 5-H or 6-H), 7.07 (1H, s, 2-H). ^{13}C NMR: δ (D_2O) 40.5 (CH_2-NH_2), 41.0 (CH-OH), 123 (6-C), 129 (1-C), 139 (3-C or 4-C). ES-MS: (20V, AcCN/H_2O) 274.3 [M+H]$^+$.

20   *Epinephrine Mercaptopropanoic Acid (39)*

Epinephrine (38) (30 mg, 0.164 mmol) was dissolved in 0.1M HCl (80 ml) and electrolysed at 2V until maximum ortho-quinone formation was observed by HPLC. The solution then had 3-mercaptopropionic acid (428 µl of 1/10 solution in 0.1M HCl, 0.491 mmol) added rapidly to the rapidly stirring solution. The solution went from

25   bright orange through green to a very deep green, almost black after 30 min. At 30 min. reaction the columning process was begun. Yield (%) 10.1mg, 0.035mmol (21%), Mp: decomposes. ^{1}H NMR δ: 1.31 (1H, m), 1.37 (1H, m), 2.75 (3H, s, NH-CH_3), 2.86 (2H, t, J= 6.7Hz, S-CH_2), 3.01 (2H, t, J= 7.1Hz, CH_2-COOH), 6.91-7.09 (2H, cluster, aromatics). ^{13}C NMR: (δ) 16.7 (CH_2-S), 28.7 (CH_2-COOH), 42 (CH_2-

30   Ar), 57.4 (CH_2-N), 108 (aromatic), 167 (aromatic). ES-MS: (CH_3CN:H_2O 1:1, -30V) 288.5 [M+H]$^+$. (H_2O, 5V):214.5 [M-amine side chain + H]$^+$, 306.3 [M+H_2O+H]$^+$.

Antibody-Binding Studies

EXAMPLE 13

5   *Biotination of monoclonal anti-progesterone antibody (Reaction Scheme 3)*

Biotinyl-N-ε-aminocaproyl-N-hydroxysuccinimide ester (*BcapNHS*) was dissolved in dry DMF (5 mg/ml), and the monoclonal *anti*-progesterone antibody (100 μl) was dissolved into 0.1 M NaHCO$_3$ (1 ml). Add the *BcapNHS* solution in DMF (50 μl) to

10   the above antibody solution in NaHCO$_3$ (1 ml); the solution was allowed to stand at room temperature for 2 hours without stirring.

The solution was then dialyzed overnight against 0.15 M NaCl (1 L) with several changes (> 4 times); the last dialysis is performed against PBS/T (1 L) for at least 4

15   hours. Finally, the biotinylated antibody was further purified by passing through a PD-10 column to give 3.5 ml of pure antibody solution, which is stored at – 20 °C for future uses.

EXAMPLE 14

20

Direct antibody-binding performance on the biosensor surface (Reaction Scheme 1)

Immobilisations

Immobilization of progesterone-linker (11 ~ 25 atoms linker)-OVA conjugates onto

25   biosensor surfaces (activated CM-5 sensor chip) was done manually aiming for a minimum immobilisation of 2000RU. Progesterone-linker (11-atoms)-OVA conjugate was immobilised at pH 3.5 and progesterone-linker (25-atoms)-OVA conjugate at pH 4.0. Flow rates were 5μL min^{-1} and 2000 RU or greater was achieved in both cases. Final immobilisations were 2524 or 2208 RU for the above two conjugates

30   respectively. The chip had a solution of OVA (5 μgmL^{-1} in running buffer) passed over the surface to help to stabilise it (10 min. at 25 μLmin^{-1}). Immobilisation buffers were 10 mM sodium formate as previously (*Steroids,* **67**, 2002, 565-572).

Binding Performance with Unmodified Antibody

Monoclonal anti-progesterone (un-modified) was passed over the surface to assess its binding (100 μgmL^{-1} in running buffer, 3 min. injection at 20 $\mu Lmin^{-1}$). This resulted in a binding of 654 RU for conjugate with 11-atoms linker, and 447 RU for the

5   conjugate with 25-atoms linker. Regeneration was effected with 50 mM glycine buffer pH = 1.5 (two pulses of 75 μL at 50 $\mu Lmin^{-1}$ flow rate) and this were adequate for complete baseline return.

Binding Performance with Biotinated Antibody

10   Biotinylated monoclonal antibody was then passed over the surface (100 μgmL^{-1} in running buffer, 3 min. injection at 20 $\mu Lmin^{-1}$) and gave a binding of 406 or 142 RU for two conjugates respectively. This result indicates that the presence of biotin-linker units on the antibody has a significant effect on the degree of binding causing a 35% reduction for the conjugate having a 11-atoms linker, and a 60% reduction for the

15   conjugate having a 25-atoms linker.

Binding Performance *with Antibody-Nanogold Particle Conjugate*

Biotinylated monoclonal antibody (100 μgmL^{-1} in running buffer, 100 μL) was mixed 1:1 with 10 nm colloidal gold–streptavidin conjugate (Sigma S9059) and vortexed,

20   and then incubated at room temperature for 10 min before injection (120 μL, 20 $\mu Lmin^{-1}$). The resulting binding was 667 RU for the conjugate having an 11-atoms linker and 257 RU for the conjugate having a 25-atoms linker. This represents a signal enhancement of 64% or 82% for both conjugates respectively. Regeneration was again done using 50 mM glycine pH 1.5 as before and found to give complete return

25   to baseline.

In order to determine the best antibody/gold volume ratio to use for competitive assay development, various ratios were optimised according to their antibody binding responses. The biotinylated monoclonal *anti*-progesterone was set at a concentration

30   of 100 μgmL^{-1}. The ratios tested were 1:1 (80μL mAb:80μL gold), 1.67:1 (100μL:60μL), 3:1 (120μL:40μL), 7:1 (140μL:20μL) and 15:1 (150μL:10μL). The same testing was then done but with running buffer instead of gold colloid to determine the degree of gold signal enhancement at each ratio. The results are

summarised below in Table 1 for the conjugate having an 11-atoms linker, and Table
2 for the conjugate with a 25-atoms linker.

TABLE 1

5

Volume Ratio mAb:gold	1	1.67	3	7	15
mAb Only	497.9		802.3	731.9	
mAb Gold	796.3	890.5	929	957.1	893.5
Enhancement	298.4		126.7	225.2	
% Enhancement	60		16	31	

TABLE 2

10

Volume Ratio mAb:gold	1	1.67	3	7	15
mAb Only	184.4		292.9	266.8	
mAb Gold	329.6	352.6	371.6	370.2	330.2
Enhancement	145.2		78.7	103.4	
% Enhancement	79		27	39	

The results clearly show that as the monoclonal antibody volume is increased without
gold labelling, one observes an increase in response up until a ratio of 3:1 antibody:

15   buffer after which it begins to decrease slowly. This pattern is seen for both
conjugates the difference being the conjugate with a 25-atoms linker has much lower
overall response than the other conjugate (11-atoms linker).

When considering the monoclonal antibody: gold colloid ratio, signal continues to

20   increase up to a ratio of 7:1 mAb:gold though flattens out at the end and from 7:1 to
15:1 a slight decrease in response is observed for both conjugates. Once again the 4-3
response is much lower than that for 4-1.

The degree of gold colloid signal enhancement (expressed in absolute terms or as a

25   percentage) is seen to peak at around 1.5:1 mAb:gold ratio and drop again until 3:1
after which a modest increase is observed up to 7:1. This suggests that gold
enhancement is maximal at around 1.5:1 ratio and is less significant at higher
antibody:gold ratios. Based on the signals obtained from the ratios above, the ratio
giving largest overall signal considering both conjugates was selected as the ratio to

use in development of a progesterone assay curve. The ratio selected was 7:1 mAb:gold.

EXAMPLE 15

Competitive Progesterone Immunoassay Using Progesterone-OVA Conjugate Surface and Antibody-Nanogold Conjugate as Flow Immunoreactant

A series of standard progesterone solutions were prepared in HBS buffer, at concentrations ranging from 0 to 1 μg/ml. Each sample (100 μl) was incubated with an equal volume (100 μl) of mixture of mAb (100 μgmL^{-1}):streptavidin/nanogold (10 nm) (7:1), incubating for 5min at 25 ^{0}C, and the resulting mixture (120 μl) passed over the chip surfaces for 6 minutes at a flow rate of 10 $\mu lmin^{-1}$. The regeneration of sensor surfaces was performed by two glycine buffer (50 mM, pH 1.5, 50 $\mu lmin^{-1}$, 2 min) pulses. The same procedure was carried out three times for each concentration.

A plot of concentrations of free progesterone versus percentage (%) bound of RU relative to zero progesterone concentration provides two standard curves for two progesterone-OVA conjugates. The standard curve for progesterone-OVA conjugate with a 25-atoms linker is shown in Figure 2. The assays for both conjugates demonstrate a very broad detection region from 1 μgmL^{-1} to < 0.1 $pgmL^{-1}$. The lowest detection limit is assessed as < 0.1 $pgmL^{-1}$ by both the 90% bound and zero – three standard deviations method, and the 50% bound values are both given in Table 3

TABLE 3

Conjugate	50% Bound (pgmL-1)	Detection Limit (pgmL-1)
11-atoms linker	1300	0.1
25 atoms linker	89	0.1

EXAMPLE 16

Biotination of monoclonal anti-progesterone antibody (Reaction Scheme 3)

5   Biotinamidocaproate-N-hydroxysuccinimide ester (BcapNHS) (Sigma Aldrich B-
     2643) was dissolved in dry DMF to make a 5 mg/mL solution. Monoclonal anti-
     progesterone (100 μL) was added to 0.1 M sodium bicarbonate solution (900 μL) and
     the BcapNHS solution was added (25 μL in 1 mL of 0.1 M sodium bicarbonate) drop-
     wise to the stirring antibody solution. The solution was stirred for 5min. before
10   leaving without stirring at room temperature for two hours. The solution was then
     dialyzed against 0.15 M NaCl at 4°C for four changes (one overnight) and then four
     changes of PBS/T (one overnight). The solution was then passed through a PD-10
     column and protein concentration determined by assumption of negligible loss of
     antibody, as the BCA method of protein concentration determination was found to be
15   unreliable due to the effects of modifying the antibody with biotin and thus changing
     the numbers of free lysine residues. Antibody was stored frozen until use. SPR
     binding studies showed $\geq$ 85% binding integrity relative to un-modified antibody.

EXAMPLE 17

20

Preparation of anti-IgG-Gold Conjugates

     Gold colloids of 25 nm, 55 nm and 70 nm were prepared by the method of citrate
     reduction (*Nature* 1973, *241*, 20-23) with some modifications to the citrate loadings.
25   All sols were produced at a 0.01% w/v $HAuCl_4$ loading. The colloid sizes were
     determined by photon correlation spectroscopy (PCS) using a Malvern Zetasizer. The
     Z_{avg} parameter was used for the 25 nm of colloid and the intensity parameter for the
     others. 30 replicates were done for the 25 nm colloid and six and five determinations
     each with 10 sub-runs was done for the other two respectively. The Zetasizer
30   determinations were validated by measuring a 20 nm commercial gold sol (Sigma
     G1652) which gave 23.0 $\pm$ 1.0 nm, n = 30 compared to 19 $\pm$ 2.1 nm by TEM. Five-
     fold concentrated gold sols were prepared by adding PEG-400 3% v/v to the sol and
     centrifuging at 14k x g for 30 min before removing supernatant and reconstituting in
     deionized water with sonication.

Anti-IgG-gold conjugates were produced by altering the pH of the sol to 8.5 with dilute NaOH and adding anti-rat IgG at 8 mg/mL in deionized water (pH = 8.5), at 10% v/v to the colloid with vortex agitation. The colloid was shaken for 5min., stored

5   at 4°C overnight and then blocked with 20% w/v BSA, 1% v/v as for the antibody.

EXAMPLE 18

Surface Immobilisation (Reaction Scheme 2)

10

A stock solution in DMF of 100 mg/mL of compound **6** was prepared. The stock was diluted 1/100 in PBS/T pH = 9.0 for injection. A new BIAcore CM5 chip (**BIAcore, Uppsala, Sweden**) had flow cell two activated with *N*-ethyl-*N*-(3-dimethylaminopropyl)-carbodiimide (EDC) and NHS (150 μL of each transferred to a

15   vial and then 200 μL mixed and 50 μL injected at 5 μL/min). The progesterone-PEG-amine solution was then quick injected at 5 μL/min, 100 μL. The surface was then deactivated with ethanolamine (50 μL, 5 μL/min) to give an immobilization binding of 638.9 RU. Flow cell one was activated and deactivated as a blank flow cell analogously to flow cell two. Flow cell three was immobilized to give a 1333.8RU

20   response. The surfaces were then washed with three pulses of 50 mM NaOH at 15 μL at 5 μL/min.

The immobilized surface of one chip has shown a very stable surface as demonstrated by more than 1100 binding and regeneration cycles without any appreciable drop in

25   antibody binding capacity and significant baseline shifts.

EXAMPLE 19

Biotin/Streptavidin Mediated Inhibition immunoassays

30

Biotinylated monoclonal antibody (100 μg/mL) was mixed with 10 nm-gold-streptavidin conjugate in volume ratios of 0.5, 1, 5, 3, 7 of antibody/gold and incubated at room temperature for 2 h. The mixture was then injected over the surface

43

in a 1:1 dilution with running buffer (60 μL, 20 μl/min) and the surface regenerated
with two pulses of 10% v/v acetonitrile in 50 mM NaOH, five replicates done in a
BIAcore wizard program. The assay was constructed in the same way but using
progesterone standards of 0, 10 fg/mL, 1, 10, 100 pg/mL, 1, 10, 100 ng/mL and 1

5   μg/mL instead of buffer. Antibody and standard were incubated at room temperature
for 5 min before injection. The 20 nm-gold-streptavidin colloid was used to construct
an assay as for the 10 nm colloid but using 0.2 M ethylene glycol in the 7:1
antibody/gold preparation and using progesterone standards of 0, 10, 100 fg/mL, 1,
10, 100, 500 pg/mL, 1, 10, 100 ng/mL.

10

Gold dilution binding tests were done for a sequential injection assay by quick
injecting biotinylated antibody (50 μg/mL, 60 μL, 20 μL/min) followed immediately
by a quick injection of 10 nm-gold-streptavidin (30 μL, 20 μL/min). After a 180 s
delay the surface was regenerated with three pulses of 20% v/v acetonitrile 200 mM

15   NaOH (20 μl, 20 μl/min.). This was done for five replicates of 0.25, 0.15, 0.10, 0.05,
0.02, 0.01 dilution of gold in 0.2 M ethylene glycol total concentration and 10% w/v
BSA total concentration. Antibody binding curves were established by setting the
flow rate to 20 μl/min. and quick injecting biotinylated antibody (60 μL) followed
immediately by 10 nm-gold-streptavidin (0.15 dilution, 1% v/v PEG-400), a 180 s

20   wait and then regeneration (three x 20% v/v acetonitrile, 200 mM NaOH) using
antibody concentrations of 0, 5, 10, 15, 25, 35, 50 μg/mL with five replicates each.
Assays were determined by mixing 70 μL of biotinylated monoclonal antibody
(concentrations of 5-30 μg/mL) with 70 μL of progesterone (0, 100 fg/mL, 1 or 5, 10,
20, 50, 100, 500 pg/mL, 1, 10, 100 ng/mL) and incubating at 25 °C for 5 min before

25   injection (60 μL, 20 μL/min throughout) immediately followed by a quick inject of 10
nm-gold-streptavidin (30 μL, with either 10% w/v BSA, 0.2 M ethylene glycol total
concentrations or 1% v/v PEG-400) followed by regeneration as for the antibody
binding.

30   Assays constructed around this format showed a LOD that was dependent upon the
concentration of monoclonal antibody used. The LOD were 150 ± 49, 23.1 ± 4.4 and
104 ± 40 pg/mL (Table 4) for concentrations of 15, 7.5 and 2.5 μg/mL of biotinylated
antibody respectively (Figure 7).

Table 4

Assay Format	mAb (µg/mL)	LOD (pg/mL)	IC-50 (pg/mL)	Sensitivity (RU mL/ng)	Enhancement Ratio
mAB only	43.75	449	1514	49	n/a
Pre-incubation (10 nm)	43.75	143 ± 35	1670 ± 100	57	1
Pre-incubation (20nm)	43.75	198 ± 57	1910 ± 150	28	1
Sequential gold (10 nm)	15	150 ± 49	1000 ± 145	32	2
Sequential gold (10 nm)	7.5	23.1 ± 4.4	460 ± 16	40	2
Sequential gold (10 nm)	2.5	104 ± 40	314 ± 21	12	2
Anti-IgG	3	20.1 ± 4.0	242.8 ± 5.1	99	8
Anti-IgG	25	246 ± 4.1	810 ± 72	226	8
Anti-IgG/gold (25 nm)	1.5	8.6 ± 3.9	151.7 ± 2.1	308	13

EXAMPLE 20

Anti-IgG Mediated Inhibition immunoassays

Anti-IgG enhancement curves were prepared by quick injecting monoclonal antibody (25 µg/mL, 60 µL, 20 µL/min) immediately followed by *anti*-rat IgG (60 µL, 10 µL/min) and then regeneration (one pulse as above) (Figure 3). *Anti*-IgG concentrations of 0, 50, 100, 200, 400, 600, 800 µg/mL were used, five replicates of each. Antibody binding curves were prepared as for the enhancement curves but keeping secondary antibody concentration fixed at 800 µg/mL and varying concentration of monoclonal antibody: 0, 0.75, 1.5, 3, 6.25, 12.5, 18.75, 25 µg/mL. Assays were set up by the same method as for the biotin/streptavidin sequential assays but using anti-rat IgG (800 µg/mL) in place of the gold and a 30s wait before regeneration with one pulse of regeneration solution. Progesterone standards of 0, 0.1, 1, 5, 10, 50, 100 pg/mL, 1, 10, 50 ng/mL were run with five replicates. In this experiment we found that if *anti*-IgG is used at a high concentration (800 mg/mL) then one observes signal enhancements of 8.1-fold (Figure 4).

Antibody binding plots were prepared as above but using *anti*-IgG-gold 25 nm (0.5 dilution in deionized water, 10% v/v PEG-400, conjugate produced using 200 μg/mL IgG 1 mL to 10 mL of colloid, pH = 8.1, three-fold concentrated by centrifugation at

5   4°C after blocking with BSA (10% w/v, 3.66 mL per 10 mL colloid), unbound IgG removed in the centrifugation). There is a 180 s wait after gold and then regeneration with one pulse.

Bindings of 25, 45, 55, and 70 nm colloids synthesized as mentioned above and used

10 as is or five times concentrated, were determined by injection of monoclonal antibody (25 μg/mL, 60 μL, 20 μL/min) followed by IgG-gold (undiluted, 60 μL, 10 μL/min) and regenerated as before. Each binding was determined in triplicate. Antibody binding plots were determined as before for the 25 nm gold-secondary antibody, 5x concentrated, using monoclonal antibody concentrations of 0, 1, 2, 5, 10, 15, 25

15 μg/mL and with the gold having a 1% v/v PEG-400 loading. Assay curves for the 25 nm-gold-IgG were prepared as before using progesterone concentrations of 0, 1, 10, 50, 100 pg/mL, 1, 10 ng/mL.

When the assay applied at low monoclonal antibody concentration (1.5 μg/mL), the

20 assay showed 13-fold enhancement (and a LOD of 8.6 ± 3.9 pg/mL. The sensitivity of the assay has increased to three-fold from that of the anti-IgG only format at 3 μg/mL and the whole assay curve has clearly shifted to lower concentration as seen in both the LOD and IC_{50} values.

25

EXAMPLE 21

Biotin / Streptavidin Mediated Assays (Figures 5 and 6).

30 Biotinylated monoclonal antibody (100 μg/mL) was mixed with 10 nm-gold-streptavidin conjugate in volume ratios of 0.5, 1, 5, 3, 7 of antibody/gold and incubated at room temperature for 2 h. The mixture was then injected over the surface in a 1:1 dilution with running buffer (60 μL, 20 μl/min) and the surface regenerated

with two pulses of 10% v/v acetonitrile in 50 mM NaOH, five replicates done in a BIAcore wizard program (figure 5). The assay was constructed in the same way but using progesterone standards of 0, 10 fg/mL, 1, 10, 100 pg/mL, 1, 10, 100 ng/mL and 1 µg/mL instead of buffer (figure 6). Antibody and standard were incubated at room

5   temperature for 5 min before injection.

The above examples are illustrations of practice of the invention.   It will be appreciated by those skilled in the art that the invention can be carried out with

10   numerous modifications and variations.   For example the haptens, the linkers, the antibodies and the concentrations used may all be varied.